Browse 16 Tykerb Medical Studies Across 204 Cities
5 Phase 3 Trial · 336 Tykerb Clinics
What Are Tykerb Clinical Trials?
A wide range of Tykerb clinical trials is currently underway. Tykerb is one of two drugs used most frequently for the treatment of advanced breast cancer. These trials are interested in discovering potential uses for Tykerb in cancers in other parts of the body and at different stages of the disease process. They are also concerned with the combination of Tykerb with other treatments. The data on these trials show that experimental treatments using Tykerb range between moderate to high safety and effectiveness.
One of the most promising studies is being done to determine whether or not breast tumors will respond to a combination of Tykerb, chemotherapy, and other common anti-cancer interventions in patients diagnosed with invasive breast cancer.
Why Is Tykerb Being Studied In Clinical Trials?
Researchers are interested in Tykerb for its potential for expanded use in the treatment of cancer at different stages of the disease process, in different parts of the body, and in combination with one or more other forms of cancer treatment.
Because the side effects of Tykerb can be moderate to severe, it is usually held in reserve and only used when cancer is found to be invasive and/or advanced. However, since this drug has proven as useful as it has in treating invasive and advanced forms of breast cancer, researchers believe that its usefulness likely has the potential to render benefits to more people with a range of cancer and cancer-related conditions.
How Does Tykerb Treatment Work?
Tykerb is an anti-cancer drug that inhibits the growth and spread of cancer cells. It is used most commonly to treat a type of cancer that most often develops in the breast. More specifically, it is used when other medications have been used and failed to prevent the spread of cancer. Tykerb is prescribed for cancer patients with breast cancer that is advanced or metastatic.
The dosage depends on several factors, including:
Tykerb is taken in the form of 250 mg tablets, orally once a day. The number of tablets prescribed will depend on the above factors.
What Are Some of the Breakthrough Clinical Trials Involving Tykerb?
Herceptin and Tykerb, head-to-head Comparison, 2008
Lapatinib and Cetuximab in Patients With Solid Tumors
Drug Use Investigation for TYKERB Tablet (All Case Investigation)
FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2
Lapatinib: a review of its use in the treatment of HER2-overexpressing, trastuzumab-refractory, advanced or metastatic breast cancer
Who Are The Key Opinion Leaders On Tykerb Clinical Trial Research?
Dr. Bella Kaufmann, director of the breast cancer unit at the cancer research center at Tel Aviv's Sheba Medical Center
James E Frampton, Division of Oncology Drug Products, Center for Drug Evaluation and Research, US Food and Drug Administration